Hypertension Medication Selector
Select your health conditions and preferences to get personalized recommendations on hypertension medications.
Recommended Medications:
When you’re trying to keep blood pressure in check, the drug you pick can feel like a gamble. Felodipine is a long‑acting dihydropyridine calcium‑channel blocker sold under the brand name Plendil. It’s praised for once‑daily dosing, but it’s not the only player on the market. Below you’ll find a side‑by‑side look at the most common alternatives, real‑world pros and cons, and practical tips for deciding which pill fits your life.
What is Felodipine (Plendil)?
Felodipine belongs to the calcium‑channel blocker (CCB) family. It relaxes the smooth muscle in arterial walls, lowering peripheral resistance and, ultimately, blood pressure. Approved in Australia in the late 1990s, Plendil is typically prescribed at 5mg or 10mg once daily, with the dose adjusted based on response and tolerability.
How Felodipine Works
The drug blocks L‑type calcium channels in vascular smooth muscle. By preventing calcium influx, the vessels stay dilated, which reduces systolic and diastolic pressure. Because it primarily targets arteries rather than the heart, felodipine has minimal effect on heart rate-a key reason many clinicians prefer it for patients with tachycardia‑related concerns.
Key Benefits & Common Side Effects
- Once‑daily dosing - simplifies adherence.
- Effective at lowering systolic pressure, especially in elderly patients.
- Low incidence of reflex tachycardia compared with older CCBs.
Typical side effects include peripheral edema, headache, flushing, and occasional dizziness. In rare cases, patients report gum overgrowth (gingival hyperplasia) - a side effect more common with non‑dihydropyridine CCBs but still worth monitoring.
Top Alternatives Compared
Below is a quick‑reference table that lines up felodipine with five frequently prescribed substitutes. All data reflect Australian prescribing guidelines and 2024 pricing where available.
| Drug | Class | Typical Daily Dose | Onset | Duration | Common Side Effects | Approx. Cost (AU$/month) |
|---|---|---|---|---|---|---|
| Felodipine (Plendil) | Dihydropyridine CCB | 5-10mg | 2-4h | 24h | Edema, headache, flushing | $12‑$20 |
| Amlodipine | Dihydropyridine CCB | 5-10mg | 6-12h | 24‑36h | Swelling, fatigue, dizziness | $8‑$15 |
| Nifedipine (extended‑release) | Dihydropyridine CCB | 30-60mg | 1-2h | 12‑24h | Headache, palpitations, edema | $10‑$18 |
| Lercanidipine | Dihydropyridine CCB | 10-20mg | 2-4h | 24h | Dry mouth, edema, tachycardia | $15‑$25 |
| Diltiazem | Non‑dihydropyridine CCB | 120‑240mg | 0.5-2h | 8‑12h | Bradycardia, constipation, edema | $12‑$22 |
| Verapamil | Non‑dihydropyridine CCB | 80‑240mg | 1‑2h | 6‑8h | Constipation, AV block, edema | $14‑$24 |
Choosing the Right Option for Your Lifestyle
Here’s a quick decision matrix that links typical patient scenarios to the most suitable drug.
- Elderly patients with isolated systolic hypertension: Felodipine or lercanidipine - both have a gentle onset and fewer cardiac effects.
- Patients prone to swelling: Amlodipine tends to cause less peripheral edema than felodipine, especially when combined with a low‑dose diuretic.
- Those needing heart‑rate control (e.g., atrial fibrillation): Diltiazem or verapamil - they slow the AV node while lowering pressure.
- Cost‑sensitive users: Generic amlodipine is usually the cheapest, followed closely by generic felodipine.
- People with liver impairment: Felodipine is heavily metabolised by CYP3A4; dose reduction may be required. Amlodipine has a more forgiving hepatic profile.
Never switch drugs without your GP’s approval. A short overlap period (e.g., a few days) can help avoid sudden spikes in blood pressure.
Switching or Combining Therapies
If you’re thinking about moving from felodipine to another CCB, ask your doctor about these steps:
- Baseline check - blood pressure, electrolytes, kidney function.
- Gradual taper - reduce felodipine by half for a week while introducing the new agent at a low dose.
- Monitor - home BP readings twice daily for two weeks.
- Adjust - fine‑tune the new medication’s dose based on readings and side‑effects.
Combining a CCB with an ACE inhibitor or a thiazide diuretic is a common strategy for resistant hypertension. The combo can improve control without dramatically raising dose‑related side effects.
Key Takeaways
- Felodipine (Plendil) is a once‑daily, long‑acting dihydropyridine CCB with modest cost.
- Common alternatives - amlodipine, nifedipine, lercanidipine, diltiazem, verapamil - differ mainly in onset, duration, and side‑effect profile.
- Pick an alternative based on age, swelling risk, heart‑rate needs, liver function, and budget.
- Switching should be gradual and medically supervised; combination therapy may be more effective for stubborn hypertension.
- Remember, Felodipine alternatives exist; the best choice is the one that fits your health picture and daily routine.
Frequently Asked Questions
Can I take felodipine with my statin?
Yes, most statins (like rosuvastatin or pravastatin) do not interact with felodipine. However, simvastatin and atorvastatin are metabolised by CYP3A4, the same pathway felodipine uses, so your doctor may lower the statin dose to avoid higher blood levels.
Why does felodipine cause ankle swelling?
Calcium‑channel blockers dilate peripheral vessels, which can raise fluid pressure in the capillaries. The excess fluid then accumulates in the lower legs, showing up as edema. A low‑dose diuretic can often counteract this effect.
Is felodipine safer than amlodipine for people with asthma?
Both drugs are considered safe for asthma because they act on blood vessels, not bronchial smooth muscle. Non‑dihydropyridine CCBs (diltiazem, verapamil) can sometimes trigger bronchospasm, so they’re less ideal for asthmatics.
How quickly will my blood pressure drop after starting felodipine?
You’ll usually see a measurable drop within 2‑4hours, with the full effect reaching a plateau after about a week of consistent dosing.
Can I switch from felodipine to an ACE inhibitor alone?
Switching is possible, but most guidelines recommend a combination approach - CCB plus ACE inhibitor - for better control. If you stop the CCB, you’ll need a higher ACE‑inhibitor dose, which can increase cough or hyperkalaemia risk.
Comments
Bill Gallagher September 30, 2025 at 18:34
When you look at the pharmacologic landscape of calcium‑channel blockers, felodipine occupies a rather interesting niche, being a long‑acting dihydropyridine that offers once‑daily dosing; however, its profile is not without nuances, especially when you consider patient‑specific factors such as age, comorbidities, and economic constraints, all of which interplay in a complex therapeutic decision‑making process, all of which interplay in a complex therapeutic decision‑making process. First, the pharmacokinetics of felodipine, characterized by extensive hepatic metabolism via CYP3A4, dictate that clinicians must be vigilant about drug‑drug interactions, particularly with agents that are strong inhibitors or inducers of this enzyme, because plasma concentrations can swing dramatically, potentially leading to adverse events or loss of efficacy. Second, the side‑effect spectrum-most notably peripheral edema, which arises from vasodilatory capillary hydrostatic pressure changes-must be weighed against the relatively low incidence of reflex tachycardia, a feature that sets felodipine apart from older dihydropyridines such as nifedipine. Third, cost considerations, while often secondary to clinical efficacy, cannot be ignored in a universal healthcare setting; generic felodipine typically resides in the $12‑$20 per month bracket in Australia, making it competitive with generic amlodipine, yet price differentials may still influence prescribing habits. Fourth, the therapeutic equivalence demonstrated in head‑to‑head trials between felodipine and lercanidipine, particularly in elderly cohorts with isolated systolic hypertension, suggests that the choice between these agents may hinge more on tolerability profiles than on blood pressure outcomes. Fifth, when patients present with high swelling risk, amlodipine's longer half‑life and more favorable edema profile often make it a preferred alternative, especially when paired with a low‑dose thiazide diuretic. Sixth, for individuals requiring heart‑rate control, such as those with atrial fibrillation, non‑dihydropyridine agents like diltiazem or verapamil provide dual benefits of vasodilation and AV‑node suppression, a duality that felodipine simply does not possess. Seventh, hepatic impairment demands dose adjustments for felodipine, given its reliance on CYP3A4 metabolism, whereas amlodipine’s metabolic pathway is more forgiving, allowing for a smoother transition in patients with compromised liver function. Eighth, the convenience of a single‑daily tablet cannot be overstated, as adherence improves dramatically when patients do not have to remember multiple dosing times, a factor that directly correlates with long‑term cardiovascular outcomes. Ninth, the potential for gingival hyperplasia, though rare with felodipine, underscores the importance of oral hygiene and regular dental check‑ups, as this side effect, more common with non‑dihydropyridines, can nevertheless manifest and affect quality of life. Tenth, clinicians should remember that abrupt cessation of felodipine can precipitate a rebound hypertensive response, so any switch to another agent should be tapered carefully, often overlapping for a week to maintain blood pressure stability. Eleventh, combination therapy-adding an ACE inhibitor or a thiazide diuretic to felodipine-has been shown to produce additive reductions in systolic pressure without a proportional increase in adverse events, a strategy that aligns well with current guideline recommendations for resistant hypertension. Twelfth, patient education about lifestyle modifications, such as sodium restriction and regular aerobic exercise, remains a cornerstone of therapy regardless of the chosen antihypertensive, because pharmacologic treatment alone rarely achieves optimal control. Thirteenth, the evolving evidence base, including recent meta‑analyses, suggests that while felodipine is effective, the marginal differences between it and other dihydropyridines are often statistically insignificant, reinforcing the notion that individual patient characteristics should drive the final selection. Fourteenth, shared decision‑making, wherein the clinician discusses the pros and cons of felodipine versus alternatives like amlodipine, nifedipine, or lercanidipine, empowers patients to adhere to the regimen they feel most comfortable with. Finally, regular follow‑up, with home blood pressure monitoring and periodic laboratory assessment, ensures that any emerging side‑effects are caught early and that the therapeutic regimen remains appropriately titrated to achieve target pressures.